Inflammatory bowel disease (IBD) is a global health burden whose existing treatment is largely dependent on anti-inflammatory agents. Despite showing some therapeutic actions, their clinical efficacy and adverse events are unacceptable. Resolution as an active and orchestrated phase of inflammation involves improper inflammatory response with three key triggers, specialized pro-resolving mediators (SPMs), neutrophils and phagocyte efferocytosis. The formyl peptide receptor 2 (FPR2/ALX) is a human G protein-coupled receptor capable of binding SPMs and participates in the resolution process. This receptor has been implicated in several inflammatory diseases and its association with mouse model of IBD was established in some resolution-related studies. Here, we give an overview of three reported FPR2/ALX agonists highlighting their respective roles in pro-resolving strategies.

炎症性肠病 (IBD) 是一种全球性的健康负担，其现有治疗在很大程度上依赖于抗炎药。尽管显示出一些治疗作用，但它们的临床疗效和不良事件是不可接受的。作为炎症的一个活跃和精心策划的阶段，消退涉及不适当的炎症反应，这三个关键触发因素是专门的促消退介质 (SPM)、中性粒细胞和吞噬细胞胞吐作用。甲酰肽受体 2 (FPR2/ALX) 是一种能够结合 SPM 并参与分解过程的人 G 蛋白偶联受体。该受体与多种炎症性疾病有关，并且在一些与分辨率相关的研究中建立了它与 IBD 小鼠模型的关联。这里，